# Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

> **NCT04564898** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 48 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab
- **DRUG:** Trifluridine/Tipiracil

## Key facts

- **NCT ID:** NCT04564898
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-25
- **Primary completion:** 2024-05-29
- **Final completion:** 2026-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564898, "Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04564898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*